Download PDF
Aktuelle Dermatologie 2022; 48(04): 162-169
DOI: 10.1055/a-1774-9766
Übersicht

Kutane Sarkome – nicht alle sind wirklich selten, die meisten „low risk“

Cutaneous Sarcomas – Not All Are Really Rare, Most Are “Low Risk”
Thomas Vogt
Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum der Universität des Saarlandes
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Correction to:

Kutane Sarkome – nicht alle sind wirklich selten, die meisten „low risk“Aktuelle Dermatologie 2022; 48(06): 282-282
DOI: 10.1055/a-1840-1393

Zusammenfassung

Die biologische und morphologische Vielfalt der Weichteilmalignome, der Sarkome, ist enorm.

Diese Übersicht fokussiert deshalb auf die 5 am häufigsten vorkommenden Weichteilmalignome. Betrachtet werden soll dabei, was der Kliniker wissen muss, was neu ist und welche Fallstricke es gibt. Ziel dieses Artikels ist es dabei, eine Übersicht zu geben sowie die Konzeptbildung darüber, womit man es im Wesentlichen zu tun hat.

Abstract

The biological and morphological diversity of soft tissue malignancies, sarcomas, is enormous. This review therefore focuses on the five most common soft tissue malignancies. Consideration will be given to what the clinician needs to know, what is new, and what are the pitfalls. The goal of this article is to provide an overview and conceptualization.



Publication History

Article published online:
14 April 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Sbaraglia M, Bellan E, Dei Tos AP. The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives. Pathologica 2021; 113: 70-84
    CrossrefPubMedSearch in Google Scholar
  • 2 Stanisz H, Pföhler C, Anagnostakos K. et al. Metastatic chondrosarcoma – current aspects of a rare event in dermatopathology. J Cutan Pathol 2012; 39: 467-470
    CrossrefPubMedSearch in Google Scholar
  • 3 Salamanca J, Dhimes P, Pinedo F. et al. Extraskeletal cutaneous chondroblastic osteosarcoma: a case report. J Cutan Pathol 2008; 35: 231-235
    PubMedSearch in Google Scholar
  • 4 Stojsic Z, Brasanac D, Stojanovic M. et al. Cutaneous composite hemangioendothelioma: case report and review of published reports. Ann Saudi Med 2014; 34: 182-188
    CrossrefPubMedSearch in Google Scholar
  • 5 Müller CS, Pföhler C, Kohn D. et al. Huge undifferentiated fibroblastic sarcoma of the foot and lower leg: impact of diagnostic delay and discussion of an entity. BMJ Case Rep 2013; 2013: bcr2013200192
    CrossrefPubMedSearch in Google Scholar
  • 6 Rouhani P, Fletcher CD, Devesa SS. et al. Cutaneous soft tissue sarcoma incidence patterns in the U.S.: an analysis of 12,114 cases. Cancer 2008; 113: 616-627
    CrossrefPubMedSearch in Google Scholar
  • 7 Casali PG, Abecassis N, Aro HT. et al. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29: iv51-iv67
    CrossrefPubMedSearch in Google Scholar
  • 8 Lebbe C, Garbe C, Stratigos AJ. et al. Diagnosis and treatment of Kaposiʼs sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC). Eur J Cancer 2019; 114: 117-127
    CrossrefPubMedSearch in Google Scholar
  • 9 Sakamoto A, Oda Y, Itakura E. et al. Immunoexpression of ultraviolet photoproducts and p53 mutation analysis in atypical fibroxanthoma and superficial malignant fibrous histiocytoma. Mod Pathol 2001; 14: 581-588
    CrossrefPubMedSearch in Google Scholar
  • 10 Bitel A, Schonlebe J, Kronert C. et al. Atypical fibroxanthoma: An analysis of 105 tumors. Dermatol Ther 2020; 33: e13962
    CrossrefPubMedSearch in Google Scholar
  • 11 Phelan PS, Rosman IS, Council ML. Atypical Fibroxanthoma: The Washington University Experience. Dermatol Surg 2019; 45: 1450-1458
    CrossrefPubMedSearch in Google Scholar
  • 12 Rosenfeld D, Alam M, Van Tine B. et al. Atypical fibroxanthoma: A malignant tumor of the skin and soft tissue. J Am Acad Dermatol 2020; 83: e429-e430
    CrossrefPubMedSearch in Google Scholar
  • 13 Miller K, Goodlad JR, Brenn T. Pleomorphic dermal sarcoma: adverse histologic features predict aggressive behavior and allow distinction from atypical fibroxanthoma. Am J Surg Pathol 2012; 36: 1317-1326
    CrossrefPubMedSearch in Google Scholar
  • 14 Helbig D, Ziemer M, Dippel E. et al. S1-guideline atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS). J Dtsch Dermatol Ges 2022; 20: 235-243
    PubMedSearch in Google Scholar
  • 15 Müller CS, Jungmann J, Pföhler C. et al. Report on immediate irradiation of a rapidly growing sarcoma of the scalp prior to wound closure. J Dtsch Dermatol Ges 2016; 14: 539-542
    CrossrefPubMedSearch in Google Scholar
  • 16 Müller CS, Schiekofer C, Korner R. et al. Improved patient-centered care with effective use of Integra(R) in dermatologic reconstructive surgery. J Dtsch Dermatol Ges 2013; 11: 537-548
    CrossrefPubMedSearch in Google Scholar
  • 17 Ugurel S, Kortmann RD, Mohr P. et al. S1 guidelines for dermatofibrosarcoma protuberans (DFSP) – update 2018. J Dtsch Dermatol Ges 2019; 17: 663-668
    PubMedSearch in Google Scholar
  • 18 Noujaim J, Thway K, Fisher C. et al. Dermatofibrosarcoma protuberans: from translocation to targeted therapy. Cancer Biol Med 2015; 12: 375-384
    PubMedSearch in Google Scholar
  • 19 Navarrete-Dechent C, Mori S, Barker CA. et al. Imatinib Treatment for Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans: A Systematic Review. JAMA Dermatol 2019; 155: 361-369
    CrossrefPubMedSearch in Google Scholar
  • 20 Ugurel S, Becker JC. Imatinib in Dermatofibrosarcoma: Targeted Therapy or Immunotherapy?. J Invest Dermatol 2017; 137: 277-279
    CrossrefPubMedSearch in Google Scholar
  • 21 Liang CA, Jambusaria-Pahlajani A, Karia PS. et al. A systematic review of outcome data for dermatofibrosarcoma protuberans with and without fibrosarcomatous change. J Am Acad Dermatol 2014; 71: 781-786
    CrossrefPubMedSearch in Google Scholar
  • 22 Massi D, Franchi A, Alos L. et al. Primary cutaneous leiomyosarcoma: clinicopathological analysis of 36 cases. Histopathology 2010; 56: 251-262
    CrossrefPubMedSearch in Google Scholar
  • 23 Cazzato G, Sergi MC, Sablone S. et al. Advanced Cutaneous Leiomyosarcoma of the Forearm. Dermatopathology (Basel) 2021; 8: 40-44
    CrossrefPubMedSearch in Google Scholar
  • 24 Chalfant V, Schriber T, Sabri A. et al. Primary Cutaneous Leiomyosarcoma of the Lower Extremity: A Case Report and Literature Review. Cureus 2021; 13: e14282
    PubMedSearch in Google Scholar
  • 25 Soares Queiros C, Filipe P, Soares de Almeida L. Cutaneous leiomyosarcoma: a 20-year retrospective study and review of the literature. An Bras Dermatol 2021; 96: 278-283
    CrossrefPubMedSearch in Google Scholar
  • 26 Vogt T, Müller CSL, Melchior P. et al. S1-Guideline Cutaneous Angiosarcomas – Update 2021. J Dtsch Dermatol Ges 2021; 19: 1801-1812
    PubMedSearch in Google Scholar
  • 27 Machado I, Giner F, Lavernia J. et al. Angiosarcomas: histology, immunohistochemistry and molecular insights with implications for differential diagnosis. Histol Histopathol 2021; 36: 3-18
    PubMedSearch in Google Scholar
  • 28 Shustef E, Kazlouskaya V, Prieto VG. et al. Cutaneous angiosarcoma: a current update. J Clin Pathol 2017; 70: 917-925
    CrossrefPubMedSearch in Google Scholar
  • 29 Milam EC, Rangel LK, Pomeranz MK. Dermatologic sequelae of breast cancer: From disease, surgery, and radiation. Int J Dermatol 2021; 60: 394-406
    CrossrefPubMedSearch in Google Scholar
  • 30 Khanna L, Prasad SR, Yedururi S. et al. Second Malignancies after Radiation Therapy: Update on Pathogenesis and Cross-sectional Imaging Findings. Radiographics 2021; 41: 876-894
    CrossrefPubMedSearch in Google Scholar
  • 31 Fineberg S, Rosen PP. Cutaneous angiosarcoma and atypical vascular lesions of the skin and breast after radiation therapy for breast carcinoma. Am J Clin Pathol 1994; 102: 757-763
    CrossrefPubMedSearch in Google Scholar
  • 32 Guadagnolo BA, Zagars GK, Araujo D. et al. Outcomes after definitive treatment for cutaneous angiosarcoma of the face and scalp. Head Neck 2011; 33: 661-667
    CrossrefPubMedSearch in Google Scholar
  • 33 Guida M, Campana LG, Curatolo P. et al. Local treatment with electrochemotherapy of superficial angiosarcomas: Efficacy and safety results from a multi-institutional retrospective study. J Surg Oncol 2016; 114: 246-253
    CrossrefPubMedSearch in Google Scholar
  • 34 Zhou G, Mei Z. Electrochemotherapy for advanced cutaneous angiosarcoma: A european register-based cohort study from the international network for sharing practices of electrochemotherapy (InspECT) – An invited commentary. Int J Surg 2019; 72: 232-233
    CrossrefPubMedSearch in Google Scholar
  • 35 Ihara H, Kaji T, Katsui K. et al. Single institutional experience of radiation therapy for angiosarcoma of the scalp without cervical lymph node metastases: Impact of concurrent chemoradiation with maintenance chemotherapy using taxanes on patient prognosis. Mol Clin Oncol 2019; 11: 498-504
    PubMedSearch in Google Scholar
  • 36 Lebellec L, Defachelles AS, Cren PY. et al. Maintenance therapy and drug holiday in sarcoma patients: systematic review. Acta Oncol 2020; 59: 1084-1090
    CrossrefPubMedSearch in Google Scholar
  • 37 Ishida Y, Otsuka A, Kabashima K. Cutaneous angiosarcoma: update on biology and latest treatment. Curr Opin Oncol 2018; 30: 107-112
    CrossrefPubMedSearch in Google Scholar
  • 38 Kollar A, Jones RL, Stacchiotti S. et al. Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. Acta Oncol 2017; 56: 88-92
    CrossrefPubMedSearch in Google Scholar
  • 39 Florou V, Rosenberg AE, Wieder E. et al. Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution. J Immunother Cancer 2019; 7: 213
    CrossrefPubMedSearch in Google Scholar
  • 40 Honda Y, Otsuka A, Ono S. et al. Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma. Oncoimmunology 2017; 6: e1253657
    CrossrefPubMedSearch in Google Scholar
  • 41 Fury MG, Antonescu CR, Van Zee KJ. et al. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J 2005; 11: 241-247
    CrossrefPubMedSearch in Google Scholar
  • 42 Albores-Saavedra J, Schwartz AM, Henson DE. et al. Cutaneous angiosarcoma. Analysis of 434 cases from the Surveillance, Epidemiology, and End Results Program, 1973–2007. Ann Diagn Pathol 2011; 15: 93-97
    CrossrefPubMedSearch in Google Scholar
  • 43 Moosazadeh M, Shafaroudi AM, Gorji NE. et al. Prevalence of oral lesions in patients with AIDS: a systematic review and meta-analysis. Evid Based Dent 2021;
    CrossrefPubMedSearch in Google Scholar
  • 44 Ramaswami R, Lurain K, Yarchoan R. Oncologic Treatment of HIV-Associated Kaposi Sarcoma 40 Years on. J Clin Oncol 2022; 40: 294-306
    CrossrefPubMedSearch in Google Scholar
  • 45 Regnier-Rosencher E, Guillot B, Dupin N. Treatments for classic Kaposi sarcoma: a systematic review of the literature. J Am Acad Dermatol 2013; 68: 313-331
    CrossrefPubMedSearch in Google Scholar
  • 46 Ferioli M, Galuppi A, Buwenge M. et al. Electrochemotherapy in Kaposi sarcoma: A systematic review. Mol Clin Oncol 2021; 14: 64
    CrossrefPubMedSearch in Google Scholar
  • 47 Oyucu Orhan S, Bilgehan Sahin A, Cubukcu E. et al. Efficacy of chemotherapeutics in classic and non-classic Kaposi sarcoma: A single-center retrospective real-world data. Bosn J Basic Med Sci 2021; 21: 746-751
    PubMedSearch in Google Scholar
  • 48 Colafigli M, Ciccullo A, Borghetti A. et al. Impact of Antiretroviral Therapy on the Risk of Recurrence in HIV-1 Infected Patients with Kaposi Sarcoma: A Multicenter Cohort Experience. J Clin Med 2019; 8: 2062
    CrossrefPubMedSearch in Google Scholar
  • 49 Piselli P, Taborelli M, Cimaglia C. et al. Decreased incidence of Kaposi sarcoma after kidney transplant in Italy and role of mTOR-inhibitors: 1997–2016. Int J Cancer 2019; 145: 597-598
    CrossrefPubMedSearch in Google Scholar